349 related articles for article (PubMed ID: 12860497)
21. Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials.
Atri A; Frölich L; Ballard C; Tariot PN; Molinuevo JL; Boneva N; Windfeld K; Raket LL; Cummings JL
JAMA; 2018 Jan; 319(2):130-142. PubMed ID: 29318278
[TBL] [Abstract][Full Text] [Related]
22. Long-term outcomes of galantamine treatment in patients with Alzheimer disease.
Lyketsos CG; Reichman WE; Kershaw P; Zhu Y
Am J Geriatr Psychiatry; 2004; 12(5):473-82. PubMed ID: 15353385
[TBL] [Abstract][Full Text] [Related]
23. Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease.
Brodaty H; Corey-Bloom J; Potocnik FC; Truyen L; Gold M; Damaraju CR
Dement Geriatr Cogn Disord; 2005; 20(2-3):120-32. PubMed ID: 15990426
[TBL] [Abstract][Full Text] [Related]
24. A 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong.
Chu LW; Yik PY; Mok W; Chung CP
Int J Clin Pract; 2007 Mar; 61(3):403-10. PubMed ID: 17313606
[TBL] [Abstract][Full Text] [Related]
25. Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with Alzheimer's disease: a randomized, double blind, placebo controlled withdrawal trial.
Scarpini E; Bruno G; Zappalà G; Adami M; Richarz U; Gaudig M; Jacobs A; Schäuble B
J Alzheimers Dis; 2011; 26(2):211-20. PubMed ID: 21606568
[TBL] [Abstract][Full Text] [Related]
26. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial.
Rockwood K; Mintzer J; Truyen L; Wessel T; Wilkinson D
J Neurol Neurosurg Psychiatry; 2001 Nov; 71(5):589-95. PubMed ID: 11606667
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomized trial.
Marder K
Curr Neurol Neurosci Rep; 2002 Sep; 2(5):389-90. PubMed ID: 12169216
[No Abstract] [Full Text] [Related]
28. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomized trial.
Kertesz A
Curr Neurol Neurosci Rep; 2002 Nov; 2(6):503-4. PubMed ID: 12359103
[No Abstract] [Full Text] [Related]
29. A prospective, double-blind, community-controlled comparison of three doses of galantamine in the treatment of mild to moderate Alzheimer's disease in a Korean population.
Suh GH; Yeon Jung H; Uk Lee C; Hoon Oh B; Nam Bae J; Jung HY; Ju YS; Kil Yeon B; Park J; Hong I; Choi S; Ho Lee J;
Clin Ther; 2004 Oct; 26(10):1608-18. PubMed ID: 15598477
[TBL] [Abstract][Full Text] [Related]
30. Effects of galantamine in patients with mild Alzheimer's disease.
Orgogozo JM; Small GW; Hammond G; Van Baelen B; Schwalen S
Curr Med Res Opin; 2004 Nov; 20(11):1815-20. PubMed ID: 15537482
[TBL] [Abstract][Full Text] [Related]
31. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease.
Morris JC; Cyrus PA; Orazem J; Mas J; Bieber F; Ruzicka BB; Gulanski B
Neurology; 1998 May; 50(5):1222-30. PubMed ID: 9595967
[TBL] [Abstract][Full Text] [Related]
32. Galantamine treatment in Alzheimer's disease with cerebrovascular disease: responder analyses from a randomized, controlled trial (GAL-INT-6).
Erkinjuntti T; Gauthier S; Bullock R; Kurz A; Hammond G; Schwalen S; Zhu Y; Brashear R
J Psychopharmacol; 2008 Sep; 22(7):761-8. PubMed ID: 18308781
[TBL] [Abstract][Full Text] [Related]
33. Long-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: multicenter trial.
Pirttilä T; Wilcock G; Truyen L; Damaraju CV
Eur J Neurol; 2004 Nov; 11(11):734-41. PubMed ID: 15525294
[TBL] [Abstract][Full Text] [Related]
34. Carotid intima-media thickness as a predictor of response to cholinesterase inhibitors in Alzheimer's disease: an open-label trial.
Modrego PJ; Rios C; Pérez Trullen JM; García-Gómara MJ; Errea JM
CNS Drugs; 2009; 23(3):253-60. PubMed ID: 19320533
[TBL] [Abstract][Full Text] [Related]
35. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.
Tariot PN; Solomon PR; Morris JC; Kershaw P; Lilienfeld S; Ding C
Neurology; 2000 Jun; 54(12):2269-76. PubMed ID: 10881251
[TBL] [Abstract][Full Text] [Related]
36. Patterns of decline and evidence of subgroups in patients with Alzheimer's disease taking galantamine for up to 48 months.
Rockwood K; Dai D; Mitnitski A
Int J Geriatr Psychiatry; 2008 Feb; 23(2):207-14. PubMed ID: 17621382
[TBL] [Abstract][Full Text] [Related]
37. Galantamine in the treatment of vascular dementia.
Brashear HR
Int Psychogeriatr; 2003; 15 Suppl 1():187-93. PubMed ID: 16191239
[TBL] [Abstract][Full Text] [Related]
38. Galantamine: a review of its use in Alzheimer's disease and vascular dementia.
Corey-Bloom J
Int J Clin Pract; 2003 Apr; 57(3):219-23. PubMed ID: 12723727
[TBL] [Abstract][Full Text] [Related]
39. Galantamine: additional benefits to patients with Alzheimer's disease.
Lilienfeld S; Parys W
Dement Geriatr Cogn Disord; 2000 Sep; 11 Suppl 1():19-27. PubMed ID: 10971048
[TBL] [Abstract][Full Text] [Related]
40. Long-term response to galantamine in relation to short-term efficacy data: pooled analysis in patients with mild to moderate Alzheimer's disease.
Kavanagh S; Howe I; Brashear HR; Wang D; van Baelen B; Todd M; Schwalen S
Curr Alzheimer Res; 2011 Mar; 8(2):175-86. PubMed ID: 21222607
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
